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Objective: We aimed to detect C-reactive protein (CRP) in neonatal saliva and evaluate its
diagnostic utility.
Study Design: Salivary and serum samples (n=89) were collected from 40 neonates. Sali-
vary CRP levels were determined using an enzyme-linked immunosorbent assay; serum
CRP was measured per hospital protocol. Correlation coefficients with 95% confidence
intervals and robust linear regression measured association while receiver–operator char-
acteristic curves described the accuracy of salivary CRP in discriminating abnormal serum
CRP thresholds of ≥10 and 5 mg/L. Corresponding sensitivities and specificities were
calculated for these salivary cutpoints.
Results: The area under the curve for salivary CRP in predicting serum CRP levels of
≥10 and 5 mg/L were 0.81 and 0.76, respectively.The corresponding sensitivity and speci-
ficity for raw salivary CRP to discriminate a serum CRP of ≥5 mg/L was 0.54 and 0.95,
respectively. The corresponding sensitivity and specificity for raw salivary CRP to discrim-
inate a serum CRP of ≥10 mg/L was 0.64 and 0.94, respectively. A statistically significant
correlation was observed between serum and salivary CRP (r =0.62, p<0.001).
Conclusion: C-reactive protein is detectable in neonatal saliva and can predict abnormal
serum CRP thresholds. Salivary CRP analysis represents a feasible screening tool for
detecting abnormal serum CRP levels.
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INTRODUCTION
C-reactive protein (CRP) is an extensively utilized biomarker for
monitoring sepsis, post-surgical complications, and inflammation
in the pediatric and neonatal populations (1). Produced in the
liver in response to IL-6, CRP levels rise rapidly during infection
and/or inflammation (1, 2). However, a current limitation to the
usefulness of serial CRP monitoring in the neonatal population
is its reliance on frequent blood draws in a vulnerable popula-
tion with limited blood volumes. Developing a non-invasive assay
for the quantification of CRP in neonates could reduce neonatal
side-effects and ultimately improve its clinical utility.
Saliva is an excellent biofluid to non-invasively monitor the
neonate. Filtered from whole blood in the salivary glands, saliva
is an important reservoir of systemic proteins and immunoglobu-
lins, electrolytes, nucleic acids, microorganisms, toxins, and drugs
Abbreviations: AUC, area under the curve; CI, confidence intervals; CRP, C-reactive
protein; CV, coefficient of variation; ELISA, enzyme-linked immunosorbent assay;
IRB, Institutional Review Board; LLOD, lower limit of detection; NEC, necrotizing
enterocolitis; NICU, Neonatal Intensive Care Unit; PVL, periventricular leukomala-
cia; ROC, receiver–operator characteristic; SIP, spontaneous intestinal perforation;
TMC, Tufts Medical Center.
(3). The collection of neonatal saliva for protein analysis is well
documented. Studies examining salivary cortisol levels in the sick
and preterm infant are plentiful, as are studies examining testos-
terone, amylase, and various antibody/antigen responses and their
association with systemic disease (4–9). Recent animal data have
demonstrated the correlation of serum and salivary CRP measure-
ments in both diseased and healthy animals (10). Additionally,
there is emerging literature supporting the use of saliva as a sur-
rogate biofluid for serum CRP monitoring in healthy adults (11,
12). However, the clinical utility of salivary CRP monitoring in the
newborn is currently unknown. The objective of this study was to
determine if salivary CRP was detectable in neonatal saliva and to
examine its diagnostic capabilities and limitations in the clinical
setting.
MATERIALS AND METHODS
STUDY POPULATION
This was a prospective Tufts Medical Center (TMC) Institutional
Review Board (IRB) approved study. Parents of infants hospi-
talized in the TMC Neonatal Intensive Care Unit (NICU) from
August 2011 to October 2012 who required serial CRP levels as
part of their routine care were asked to participate. There were
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no exclusion criteria based on gender, genetic disorder, disease
process, or clinical status.
PROCEDURES
Neonatal salivary samples were collected within 4–12 h of clinically
indicated serum CRP levels. For those infants receiving enteral
nutrition, every attempt was made to collect saliva 1 h prior to
a feed to avoid breast milk or formula contamination. Salivary
samples were collected with protocols previously established in
our laboratory (13). Samples were obtained over 5–15 s using a
1 mL syringe, wings removed, attached to low-wall suction. The
syringe was weighed pre- and post-salivary collection to determine
salivary volume. Saliva was then placed in 65µL of a protease
inhibitor (SigmaFAST™, St. Louis, MO, USA) and RNAprotect
Saliva (Qiagen™, Venlo, Limburg, Netherlands) in a 1:10 concen-
tration for salivary protein stabilization (13–15). Samples were
vortexed, placed on ice, and subsequently stored at −80°C for
several weeks up to 8 months before processing.
Total protein concentration in each sample was determined
with the NanoDrop™ Spectrophotometer 1000 (Thermo Fisher
Scientific, Inc., Waltham, MA, USA). Salivary CRP concentrations
were determined with a commercial electrochemiluminescence
immunoassay (MesoScale Discovery™, Rockville, MD, USA) per
manufacturer’s instructions. All samples were run in triplicate and
plotted against a standard curve for CRP quantification. Serum
CRP measurements were determined in the TMC hospital labora-
tory using the UniCel DxC 600i immunoassay analyzer (Beckman
Coulter, Inc., Brea, CA, USA).
STATISTICAL ANALYSIS
Statistical analyses used the SAS statistical package, version 9.2
(SAS Institute, Cary, NC, USA) and R (version 2.15.1). Medians
and interquartile ranges were used to summarize demographic
and clinical characteristics of the patients. Spearman correlation
coefficients and their 95% confidence intervals (CI) were used
to measure the association between salivary protein and volume,
serum CRP and raw salivary CRP, and serum CRP and salivary
CRP normalized with either total protein concentration or vol-
ume. All associations fit a robust linear regression model. We
minimized the minimum absolute deviations of the residuals
(MAD) using the method of iterative least squares (16). This was
calculated using the “lm” function in the R Project for Statistical
Computing (17).
The discrimination of the salivary CRP levels for predicting
abnormal serum CRP levels were calculated and compared using
the area under the ROC curve (AUC) and corresponding CI
using the method of Delong et al. (18). To examine the prac-
tical application of the salivary CRP levels, the sensitivity and
specificity, and corresponding 95% CI, using 2000 bootstrap repli-
cations, were calculated for cut-offs based on the upper limit
of each range. The sensitivities, specificities, and corresponding
receiver–operator characteristic (ROC) curves were created using
the “pROC” package in R. Optimal salivary CRP cutpoints were
determined using Youden’s J-statistic (19). To address the fact
that multiple samples were collected from 22 out of 35 of the
patients in the study population, an additional sensitivity analysis
was conducted on the dataset by randomly selecting one paired
measurement from these patients.
RESULTS
There were 40 infants initially enrolled in this study. As designated
by the study design, five patients were excluded from the analy-
sis because their salivary samples were obtained >12 h from the
associated serum CRP level. Aside from this, no other patients
or samples were excluded for any reason. From the remaining
35 patients, 89 salivary samples were ultimately included in the
final analysis. Subjects’ gestational ages and birth weights ranged
from 23 to 42 weeks and 490 to 3950 g, respectively. The majority
of serum CRP levels were obtained for post-operative monitor-
ing (44/89 salivary samples), followed by necrotizing enterocolitis
(NEC) or spontaneous intestinal perforation (SIP) (33/89 salivary
samples), and infectious disease (12/89 salivary samples) (Table 1).
Salivary CRP was detected in 97% of the samples ana-
lyzed (86/89) with a median sample volume of 35.4µL (IQ
range= 18.2–64.9µL). In contrast, the minimal volume needed
for the measurement of serum CRP was 200µL. The median
salivary CRP concentration was 3.1 ng/mL (IQ range= 0.4–
22 ng/mL); the median serum CRP concentration was 106.1 mg/L
(IQ range= 4.8–127.2 mg/L). The lower limit of detection (LLOD)
for salivary CRP was 4.5 pg/mL. Intra-assay coefficients of vari-
ation (CVs) at low (10 pg/mL) and high (394 474 pg/mL) con-
centrations were 56 and 9%, respectively. Inter-assay CVs at low
(9 pg/mL) and high (752 124 pg/mL) concentrations were both
10%. The CV of all triplicate samples was dependent upon CRP
concentration. Samples with CRP concentrations at the lower limit
of our assay detection had much higher CVs than samples within
range (CVs ranged from 1.9 to 86.7%; Figure 1).
There was a statistically significant correlation between serum
and raw salivary CRP concentrations [r = 0.62, p< 0.001 (95%
CI: 0.47–0.73); Figure 2]. However, given varying volumes of
saliva obtained with each sample, we normalized the data. His-
torically, salivary volume has been used to normalize analyte con-
centration across samples (20–25). However, in our study, salivary
protein concentration was weakly associated with sample volume
[r = 0.35, p= 0.01 (95% CI: 0.11–0.55)]. Thus, we examined the
Table 1 | Demographic characteristics of study population.
Total patients (n) 35
Birth weight (g) 1774 (946–2253)a
Current weight (g) 2102 (1375–2625)a
Gestational age (weeks) 30.4 (26–34.8)a
PCA at evaluation (weeks) 34.5 (31.6–38.1)a
Male:Female 1.8:1
Total salivary samples (n) 89
Salivary samples per patient 2 (1–3)a
Serum CRP (mg/L) 106.1(4.8–127.2)a
Raw Salivary CRP (ng/mL) 3.1 (0.4–22)a
Salivary protein concentration (mg/dL) 3.1 (2–5.9)a
Salivary volume (µL) 35.4 (18.2–64.9)a
aMedian (25th–75th interquartile range).
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FIGURE 1 | Graph illustrating the logarithmic relationship between
coefficient of variation and salivary CRP concentration. The
transformation used was log(x )−1.
FIGURE 2 | Graph illustrating the estimated parameters from a
regression of salivary CRP levels on serum CRP levels. Both salivary
CRP and serum CRP were power transformed; salivary CRP was
transformed by taking the natural log of salivary CRP (ng/mL)+1. Serum
CRP was transformed using a Box–Cox transformation with a lambda of
0.12; n=89 salivary samples.
relationship of raw salivary CRP levels to protein concentration
and volume separately. Raw salivary CRP concentrations were
more strongly associated with protein concentration as compared
to volume [r = 0.62, p< 0.001 (95% CI: 0.48–0.74) and r = 0.52,
p< 0.001 (95% CI: 0.33–0.69)]. Based on these data, we normal-
ized salivary samples using total protein concentration. A statisti-
cally significant association was also observed between serum CRP
and the protein-adjusted salivary CRP [r = 0.57, p< 0.001 (95%
CI: 0.40–0.69)]. Similar associations were seen between serum
CRP and raw and protein-adjusted salivary CRP in a sensitiv-
ity analysis limited to one randomly selected sample per patient
[r = 0.68, p< 0.001 (95% CI: 0.44–0.82) and r = 0.60, p< 0.001
(95% CI: 0.33–0.78), respectively].
Next, we examined the ability of salivary CRP to predict serum
CRP thresholds of ≥5 and 10 mg/L (Figures 3 and 4). Raw sali-
vary CRP demonstrated good diagnostic accuracy at predicting a
FIGURE 3 | Receiver–operator characteristic (ROC) curve of raw salivary
CRP for predicting serum CRP ≥5 mg/L. Sensitivity is plotted against
specificity for salivary CRP thresholds between 0 and 7.18 ng/mL;
AUC=0.76.
FIGURE 4 | Receiver–operator characteristic (ROC) curve of raw salivary
CRP for predicting serum CRP ≥10 mg/L. Sensitivity is plotted against
specificity for salivary CRP thresholds between 0.01 and 20.35 ng/mL;
AUC=0.81.
serum CRP of ≥10 mg/L (AUC= 0.81, 95% CI: 0.72–0.90) and
demonstrated fair diagnostic accuracy at predicting a serum CRP
of ≥5 mg/L (AUC= 0.76, 95% CI: 0.66–0.87). Protein-adjusted
salivary CRP demonstrated fair diagnostic accuracy at predict-
ing a serum CRP of ≥10 and ≥5 mg/L [AUC= 0.78 (95% CI:
0.68–0.87) and 0.75 (95% CI: 0.65–0.86)], respectively. Again,
similar AUC results for raw and protein-adjusted salivary CRP
were seen in a sensitivity analysis limited to one randomly selected
sample per patient. Raw salivary CRP demonstrated good and
fair diagnostic accuracy at predicting a serum CRP of ≥10 and
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5 mg/L [AUC= 0.86 (95% CI: 0.74–0.99) and 0.78 (95% CI: 0.63–
0.93)]. Protein-adjusted salivary CRP demonstrated good and
fair diagnostic accuracy at predicting a serum CRP of ≥10 and
≥5 mg/L [AUC= 0.82 (95% CI: 0.67–0.98) and 0.77 (95% CI:
0.61–0.92)].
Finally, statistically determined salivary cut-offs were generated
optimizing sensitivity and specificity for raw and protein-adjusted
salivary CRP. A raw salivary CRP concentration of 4.84 ng/L had
a corresponding sensitivity and specificity of 0.64 and 0.94 in
accurately predicting a serum CRP level of ≥5 mg/L and a corre-
sponding sensitivity and specificity of 0.54 and 0.95 in accurately
predicting a serum CRP of≥10 mg/L (Table 2). A protein-adjusted
salivary CRP concentration of 133.38 ng/mL had a corresponding
sensitivity of 0.61 and specificity of 0.84 in accurately predicting a
salivary CRP of ≥5 mg/L. A protein-adjusted salivary CRP cut-off
of 166.11 ng/mL had a similar sensitivity and specificity (0.67 and
0.84, respectively) in predicting a salivary CRP of ≥10 mg/L.
DISCUSSION
To our knowledge, this is the first study to detect, quantify, and
demonstrate that salivary CRP is a good measure of discrimina-
tion for clinically relevant serum CRP thresholds. Additionally,
we observed the modest yet statistically significant association
between CRP measured in neonatal saliva and serum, which has
been supported in previously published research in healthy adults
and animals (10–12). These data together illustrate the potential of
salivary CRP as a routine screening assay for the at-risk newborn.
There is a strong need for better surveillance and monitoring
for infants at risk of infection and post-surgical complications.
Neonatal sepsis is estimated to occur in 1–21 newborns per 1,000
live births, resulting in significant morbidity and mortality. The
risk of periventricular leukomalacia (PVL), a form of white matter
brain injury associated with poor neurological and developmental
outcomes, increases twofold for every case of neonatal bacterial
sepsis (26, 27). Furthermore, estimated sepsis-associated mortal-
ity rates are as high as 69% in the premature neonatal population
(26). CRP has been previously validated as a non-specific, but
nevertheless, informative biomarker for the identification of new-
borns at risk for these sequelae. Current neonatal care guidelines
for sepsis monitoring include frequent invasive surveillance meth-
ods and the use of prophylactic antibiotics. Non-invasive salivary
diagnostics using a dichotomous variable salivary CRP screening
test, could markedly improve our ability to care for these infants
by alerting the care-giver to abnormal serum levels without the
need for repeated phlebotomy.
Historically, the majority of published salivary reports have
used volume and flow rate to normalize salivary analytes across
samples (21–23). However, hydration status directly impacts sali-
vary flow, and the use of volume for normalization may not be
ideal, particularly in the neonatal population where collection of a
standardized volume of saliva may not always be possible (24, 25).
We addressed this issue by examining the relationship between
salivary CRP levels with total protein concentration and found
that raw salivary CRP levels showed the strongest predictive value
of an abnormal serum CRP level. While there are obvious advan-
tages to using the raw salivary CRP levels, including a more rapid
interpretation of salivary CRP levels, future studies will need to be
performed to assess the most accurate and clinically informative
normalization method in the newborn.
Our feasibility study provides initial support for the quan-
tification of salivary CRP in neonates using broadly available
laboratory-based technology. A limitation of this pilot study is
the range of inter- and intra-patient variation. We believe that
these findings represent the technical limitations of the assay,
specifically at the level of threshold detection. Variation between
replicates sharply decreased at higher salivary CRP concentrations
compared to samples with lower levels of the biomarker. In devel-
oping this non-invasive assay for infants with weights as low 490 g
from as little as 2µL of saliva, it is not unexpected that some
of our samples had suboptimal performance. Furthermore, some
variability can be attributed to the possible circadian variation
observed between serum and salivary CRP, micro-injury to the
tissue, localized inflammation of the mucosa, gestational age of
the patient, mode of delivery, and salivary gland maturation (12,
27–30). However, emerging analytic devices, such as microfluidic
immunosensor chips and lab-on-a-chip devices, have five times
the sensitivity of traditional enzyme-linked immunosorbent assays
(ELISAs) used in this study, and may be used in multiplex formats
to detect dozens of biomarkers simultaneously from a single sam-
ple source (31–34). As these technologies continue to evolve, they
have the potential to become incorporated into the NICU for rapid
non-invasive assessment of the newborn. We believe that the vari-
ation seen between sample replicates at the level of detection in our
study will be minimized with such platforms and that this current
Table 2 | Optimal salivary CRP cutpoints associated with maximal sensitivity and specificity in predicting abnormal serum CRP levels.
Metric Optimal salivary
CRP cutpoint
(ng/mL)a
Sensitivity
(95% CI)b
Specificity
(95% CI)b
AUC
(95% CI)c
Raw salivary CRP predicting serum CRP ≥5 mg/L 4.84 0.54 (0.43–0.66) 0.95 (0.84–1.00) 0.76 (0.66–0.87)
Raw salivary CRP predicting serum CRP ≥10 mg/L 4.84 0.64 (0.52–0.76) 0.94 (0.84–1.00) 0.81 (0.72–0.90)
Protein-adjusted salivary CRP predicting serum CRP ≥5 mg/L 133.38 0.61 (0.50–0.73) 0.84 (0.68–1.00) 0.75 (0.65–0.86)
Protein-adjusted salivary CRP predicting serum CRP ≥10 mg/L 166.11 0.67 (0.71–0.97) 0.84 (0.55–0.79) 0.78 (0.68–0.87)
aOptimal cutpoints were determined using Youden’s J-statistic (19).
bSensitivity and specificity confidence intervals were determined using 2000 bootstrap replications.
cConfidence intervals calculated using the method of Delong et al. (18).
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limitation will ultimately not pose as a barrier to integration into
clinical care.
In conclusion, we have shown that salivary CRP is readily
detectable in the neonate and demonstrates good accuracy at dis-
criminating between clinically relevant serum CRP thresholds.
Serial salivary CRP screening of the at-risk patient may represent
a feasible and safe alternative to frequent serum sampling by alert-
ing the care-giver to a potential infection, inflammatory process,
and/or surgical complication in the neonatal population. Future
studies establishing normative values across gestational age and
weight, as well as incorporating related protein markers of sepsis
and inflammation, may provide even more specific assessment of
the at-risk newborn. Ultimately, integrating salivary biomarkers
into neonatal care could provide the most effective and minimally
invasive approach to accurate sepsis and inflammation screening
in this vulnerable population.
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